Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 0.65 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8084877 | 0.85 | HDAC1 (0.69) | HDAC1NAMPTHDAC2HDAC3KCNH2 | |
| SCHEMBL3783228 | 0.79 | HDAC1 (1.00) | HDAC1HDAC2HDAC3 | |
| SCHEMBL8083578 | 0.79 | HDAC1 (0.60) | HDAC1NAMPTHDAC2HDAC3KMT2A | |
| SCHEMBL8082868 | 0.77 | HDAC1 (0.63) | HDAC1NAMPTHDAC2HDAC3KCNH2 | |
| SCHEMBL3642190 | 0.76 | HDAC1 (0.75) | HDAC1HDAC2HDAC3KCNH2 | |
| SCHEMBL210160 | 0.75 | HDAC1 (0.68) | HDAC1NAMPTHDAC2HDAC3 | |
| SCHEMBL2734093 | 0.75 | HDAC1 (0.68) | HDAC1NAMPTHDAC2HDAC3 | |
| SCHEMBL1691047 | 0.73 | HDAC1 (0.67) | HDAC1NAMPTHDAC2HDAC3KMT2A | |
| SCHEMBL26686761 | 0.72 | HDAC1 (0.72) | HDAC1NAMPTHDAC2HDAC3KMT2A | |
| SCHEMBL4936094 | 0.72 | HDAC1 (0.84) | HDAC1NAMPTHDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461189-B2 | Pyridyl derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461189-B2 | Pyridyl derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20100324092-A1 | PYRIDYL AND PYRIMIDINYL DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-12-23 | — | — | US | disclosed |
| WO-2009005638-A2 | PYRIDYL AND PYRIMIDINYL DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324092-A1 | PYRIDYL AND PYRIMIDINYL DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | BRDT, HDAC5, HDAC1 | HDAC1 3/4885NAMPT 63/4885HDAC2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.